In a randomised, double-blind, placebo-controlled trial, citalopram (20 mg p.o. id) and desipramine (a NET inhibitor with mild selectivity over SERT, see Table 1; up to 25 mg p.o. three times a day (tid)) were compared in 48 nondemented PD patients with depression [146, 147]. This evidence concerns the gene SLC6A2 and Parkinson disease.